Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* healthy men or women,~* age 18 to 45 years inclusive;~* normal medical history and physical examination~* Women must have a negative pregnancy test.~Exclusion Criteria:~* travel to a cholera endemic area in the previous 5 years;~* abnormal stool pattern or regular use of laxatives;~* Currently active unstable or undiagnosed medical conditions~* current or recent antibiotic use;~* pregnancy or nursing;~* Previously received a licensed or investigational cholera vaccine~* History of cholera or enterotoxigenic E. coli infection~* History of Guillain-Barré Syndrome~* Received or plans to receive any other licensed vaccines, except for seasonal influenza~* Recipient of bone marrow or solid organ transplant~* Malignancy (excluding non-melanotic skin cancers) or lymphoproliferative disorders diagnosed or treated during the past 5 years~* Use of systemic chemotherapy in the previous 5 years prior to the study~* any immunosuppressive medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- PXVX0200 Lot A (Type: EXPERIMENTAL): PXVX0200 (Lot P700-1CA03) Single dose; liquid suspension after reconstitution with buffer; \> 2x10\^8 CFU in a liquid suspension
- PXVX0200 Lot B (Type: EXPERIMENTAL): PXVX0200 (Lot P700-3CA03) Single dose; liquid suspension after reconstitution with buffer; \> 2x10\^8 CFU in a liquid suspension
- PXVX0200 Lot C (Type: EXPERIMENTAL): PXVX0200 (Lot P700-6BA03) Single dose; liquid suspension after reconstitution with buffer; \> 2x10\^8 CFU in a liquid suspension
- Placebo (Type: PLACEBO_COMPARATOR): Placebo physiological saline

Based on this trial design, predict the completion outcome and termination type (if applicable).